Mission Pharmacal Header

Mission Pharmacal Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"Cyan Bio","sponsor":"Adge Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Adge Pharmaceuticals Partners with Cyan Bio of Korea to Advance Treatments for Rare Pediatric Diseases in Asian Countries","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Cyan Bio"},{"company":"Bridge Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BridgeBio Pharma Announces Positive Phase 2 Data for Limb-girdle Muscular Dystrophy Type 2i (LGMD2i)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Bridge Biotherapeutics"}]

Cyan Bio

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Adge Pharmaceuticals Partners with Cyan Bio of Korea to Advance Treatments for Rare Pediatric Diseases in Asian Countries

Details:

Adge has secured a global license to RO269228, a clinical stage oral small molecule originally developed by Roche for osteoporosis. RO269228, also known as elocalcitol, is a vitamin D analog which has demonstrated efficacy and safety in multiple Phase 2 clinical trials.

Lead Product(s): Elocalcitol

Therapeutic Area: Genetic Disease Product Name: RO269228

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Adge Pharmaceuticals

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership April 25, 2022

ASK
US

Upload
your Pipeline Activity

Bridge Biotherapeutics

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

BridgeBio Pharma Announces Positive Phase 2 Data for Limb-girdle Muscular Dystrophy Type 2i (LGMD2i)

Details:

43% increase in ratio of glycosylated alpha-dystroglycan to total αDG from baseline were measured for BBP-418, across all three dosing cohorts, signifying the oral therapy has potential to address both the root cause of LGMD2i and drive functional improvements for patients.

Lead Product(s): Ribitol

Therapeutic Area: Genetic Disease Product Name: BBP-418

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 14, 2022

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY